Ipilimumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ipilimumab: From Metastatic Melanoma to Choroideremia
One-Sentence Summary
Ipilimumab was originally used to treat metastatic melanoma. The TxGNN model predicts it may be effective for choroideremia (an inherited retinal degeneration), but there are currently 0 clinical trials and 0 publications supporting this direction. The high score appears to be a model artifact rather than a reflection of real evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Metastatic melanoma |
| Predicted New Indication | Choroideremia |
| TxGNN Prediction Score | 99.06% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the data compiled for this report. Ipilimumab is known to block CTLA-4, which enhances T-cell priming and anti-tumour immunity. This mechanism underlies its efficacy in metastatic melanoma.
Choroideremia is a single-gene, X-linked retinal degeneration caused by loss of the CHM (REP1) gene. It is not driven by tumour growth or by a failure of immune surveillance. No plausible biological link between CTLA-4 blockade and this disease was identified.
The very high TxGNN score (0.99) therefore appears to be a graph-based prediction artifact. No trials or literature back it up, so the prediction should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN14598P | YERVOY INJECTION CONCENTRATE 5MG/ML | Injection, solution, concentrate |
This is a single-ingredient product with a valid registration, and it is an injectable formulation. The approved indication text was not available in the data compiled for this report.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (anti-CTLA-4 monoclonal antibody), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert; immune-related adverse events (e.g. liver, thyroid, skin, bowel) are typically monitored for checkpoint inhibitors |
| Handling Protection | Please refer to the package insert and local institutional policy for handling of antineoplastic biologics |
Safety Considerations
- Drug Interactions: The interaction query returned 100 records. The first 20 reviewed include:
- Major: anticoagulants, including apixaban, betrixaban, bivalirudin, dalteparin, desirudin, edoxaban, argatroban and danaparoid.
- Moderate: corticosteroids (hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisolone, prednisone), metronidazole, tinidazole, naltrexone, rosuvastatin and simvastatin.
Corticosteroids matter in practice because they are commonly used to manage immune-related adverse events, and this interaction should be considered when planning care.
For warnings and contraindications, please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone (L5). There are no trials or publications, and no plausible mechanistic link between CTLA-4 blockade and a monogenic retinal degeneration such as choroideremia. Safety label data are also incomplete.
To proceed, the following is needed:
- Mechanistic evidence for any biological role of CTLA-4 or immune pathways in choroideremia
- Preclinical data in relevant retinal disease models
- Package insert warnings and contraindications for Singapore (HSA), and the approved indication text
- Detailed mechanism of action data (MOA)
- A safety assessment for ocular use, since immune-related adverse events could further harm an already degenerating retina
Other predictions for this drug are more credible, because they are melanoma subtypes within or close to the approved indication. For example, non-cutaneous melanoma has a completed Phase 2 trial of nivolumab plus ipilimumab in uveal melanoma. These would be better candidates to prioritise for further evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.